Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023 | Last Trade: US$81.14 10.88 15.49

SAN DIEGO / Dec 19, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42^nd annual J.P. Morgan Healthcare Conference on January 8, 2024.

The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast.

Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit www.dexcom.com.

Stock Quote

Last Trade:	US$81.14
Daily Change:	10.88 15.49
Daily Volume:	7,462,154
Market Cap:	US$31.690B

May 01, 2025 Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program April 10, 2025 DexCom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System April 01, 2025 Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems March 25, 2025 Dexcom Appoints Jon Coleman as Chief Commercial Officer March 10, 2025 Dexcom Appoints Renée Galá to Board of Directors LOAD MORE NEWS

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE